Skip to content

Maravai LifeSciences

US · MRVI #3116 by market cap Listed 2020
6.98 -0.21 -2.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 6.86 -4.59%
After-hours 6.98 0.00%
9.004.376.982026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MRVI?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +44.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 9.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth F

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -40.5% Better than 1%
Free cash flow CAGR (3Y) -21.8% Better than 17%
Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 18.3% Better than 15%
Operating margin -69.2% Better than 8%
Net margin -70.4% Better than 8%
Return on equity -48.6% Better than 9%
Return on invested capital -18.1% Better than 14%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -19.2% Better than 32%
6-month return 58.6% Better than 96%
12-month return (ex latest month) 95.2% Better than 95%
Distance below 52-week high 25.9% Better than 49%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.6x Better than 90%
Debt to assets 47.3% Better than 18%
Interest coverage -7.7x Better than 14%
Free cash flow / net income 235.6% Better than 81%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 41.5% Better than 60%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.43%
1M -3.06%
3M -15.80%
6M +57.56%
YTD +114.77%
1Y +104.09%
3Y +41.58%
5Y -81.37%

Key statistics

Price & volume

Prev close
7.19
Open
7.06
Day range
6.91 - 7.17
Avg price
7.00
Volume
1.79M
Turnover
12.50M
Amplitude
3.62%
52-week range
2.80 - 9.42

Valuation

P/E
-7.76
P/E (TTM)
-15.86
P/B
5.32
EPS
-0.90
Net profit
-134.33M
Net assets
195.82M

Share structure

Market cap
1.04B
Float cap
716.18M
Shares out
149.25M
Float shares
102.60M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-11-20
52-week range 63% of range
2.80 9.42

25.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-9.03M net over the window

Short interest

Shares short
14.05M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Maravai LifeSciences (MRVI)?

Maravai LifeSciences last traded at 6.98. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Maravai LifeSciences's market cap?

About 1.04B.

What is the P/E ratio of Maravai LifeSciences?

The trailing twelve-month P/E is -15.86, below its own 5-year average of 3.54 — toward the bottom of its historical range (0.40% percentile). See the Valuation tab for the full history.

Does Maravai LifeSciences pay a dividend?

Maravai LifeSciences does not currently pay a regular dividend.

Is Maravai LifeSciences a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 9.88, which implies 41.5% upside from the current price. This is not investment advice.

What is Maravai LifeSciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Maravai LifeSciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Maravai LifeSciences discussion 0 comments

Add a comment